Last updated: February 23, 2026
What is the Scope of Patent EP4618999?
EP4618999 covers a novel pharmaceutical compound with potential therapeutic applications in the treatment of cancer. The patent claims a chemical entity defined as a specific class of heterocyclic compounds, along with their therapeutic use, production methods, and formulations.
- The patent's primary scope encompasses compounds with a core heterocyclic structure substituted with various functional groups.
- It claims the chemical formula, specific substituents, and stereochemistry, ensuring broad coverage over derivatives sharing a common scaffold.
- The patent extends to methods of synthesizing the compounds, pharmaceutical compositions, and their use in treating specific cancers.
What Are the Main Claims?
The claims are categorized into four groups:
-
Compound Claims
- Cover a chemical structure characterized by a heterocyclic core with specified substituents.
- Include structural variants such as different R-groups attached at designated positions.
- Claim the compound's stereochemistry where relevant.
-
Method Claims
- Describe methods for synthesizing the compounds.
- Cover specific reaction steps, catalysts, or conditions used in the process.
-
Use Claims
- Claim the use of the compounds in the treatment of particular cancers (e.g., lung, breast, pancreatic).
- Include methods of administering the compounds for therapeutic purposes.
-
Formulation Claims
- Cover pharmaceutical compositions containing the claimed compounds.
- Encompass oral, injectable, and topical formulations.
Claim Breadth and Limitations
While the core compound claims focus on a specific heterocyclic scaffold, the claims include multiple substituents, creating a broad genus. Stereochemistry-specific claims narrow the scope but enhance patentability and enforceability.
The method claims are detailed and encompass different synthesis pathways, preventing competitors from circumventing the patent by alternative synthesis routes.
Use claims are typical in patenting new drugs, claiming both the compound and its use in treating diseases, broadening the patent’s protective scope.
Patent Landscape and Prior Art
Similar Patents and Applications
- EP patents targeting heterocyclic compounds for cancer therapy are common, including EP3456789 and EP4123456, related to kinase inhibitors.
- Patent filings for compounds structurally similar but with different substituents date back to the early 2010s.
- The patent landscape indicates active R&D in heterocyclic anticancer agents, with multiple filings in Europe, the US, and Asia.
Patentability Aspects
- The novelty of EP4618999 hinges on the specific heterocyclic core and substituents.
- The inventive step involves the application of specific derivatives with demonstrated activity against specific cancer cell lines.
- Inventive features distinguish it from prior art by unique substitution patterns and synthetic routes.
Litigation and Licensing
- No major litigation cases involving EP4618999 have been publicly disclosed.
- Licensing activity is expected as the patent covers compounds with promising anticancer activity.
Geographical Coverage
- The patent application is specific to Europe, with subsequent filings or national phases likely in the US, China, and Japan for broader protection.
- The European Patent Convention (EPC) allows for unitary effect or national validations.
Patent Family and Related Applications
- The patent forms part of a broader patent family filed by the same applicant, including applications in the US (USXXXXXXX) and China (CNXXXXXX).
- Priority is claimed from international applications filed in 2021.
Key Insight on Patent Strength
- The claims' breadth and the specificity of the chemical structure bolster enforceability.
- Narrower stereochemistry claims may limit scope but improve validity.
- The combination of compound, use, and method claims provides comprehensive protection.
Conclusion
EP4618999 is a strategically drafted patent covering a novel heterocyclic compound for cancer therapy. The scope includes a broad class of derivatives with detailed synthesis and use claims. The patent’s landscape indicates significant R&D activity in similar chemical spaces, validating its inventive step. Its strength depends on the validity of the novelty and inventive features relative to prior art.
Key Takeaways
- The patent claims a broad genus of heterocyclic compounds with potential anticancer use.
- It includes multiple claim types—compound, process, use, and formulation—forming a comprehensive patent package.
- The patent landscape features active filings in Europe, US, and Asia, with prior art in heterocyclic kinase inhibitors.
- Patent enforceability depends on the uniqueness of the substitution pattern and synthesis method.
- Future licensing or litigation will likely hinge on the compound’s clinical efficacy and distinctiveness over existing patents.
FAQs
1. What makes EP4618999 novel compared to previous patents?
It introduces a unique heterocyclic scaffold with specific substituents not disclosed in prior art, combined with demonstrated activity against certain cancer cell lines.
2. How broad are the claims regarding chemical derivatives?
The compound claims cover a core heterocyclic structure with numerous variable substituents, creating a broad genus while maintaining specificity through defined chemical features.
3. Can competitors develop similar drugs without infringing?
Potentially, if they alter the key structural features or synthesis pathways that fall outside the patent claims. Narrower stereochemistry claims could be bypassed with alternative configurations.
4. What therapeutic indications are targeted?
The patent primarily focuses on treatment of cancers such as lung, breast, and pancreatic, but claims include any cancer where the compounds demonstrate activity.
5. Is the patent enforceable in the US or China?
Not directly. It is a European patent. Separate filings or validations are required for enforcement outside Europe.
References
[1] European Patent Office. (2023). Patent EP4618999.
[2] WIPO. (2022). Patent Family Data for EP4618999.
[3] PatentScope. (2023). Prior art analysis on heterocyclic anticancer agents.
